$165.00▼ 9.00 (5.17%)
Real-time prices · US MarketsConsensus analyst target of $314.81 is 91% above current price.
Quality
9
Health
6.9
Growth
9
Valuation
9.1
Sentiment
7.6
Analyst Target
$314.81
▲ +90.8% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
8.3×
price-to-earnings
Forward P/E
14.5×
next 12 months est.
Market Cap
$22.1B
market capitalization
Div Yield
0.00%
dividend yield
Profit Margin
52.8%
net profit margin
Gross Margin
77.3%
revenue minus COGS
ROE
138.1%
return on equity
Beta
0.27
vs S&P 500
52-Week Range
$163 — $480
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Alnylam Pharmaceuticals, Inc. right now?
Alnylam Pharmaceuticals, Inc.'s Q·Score is 8.4/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $314.81 is 91% above current price. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for ALNY?
The consensus price target for ALNY is $314.81, based on ratings from 27 Wall Street analysts. This is 90.8% above the current price of $165.00. Price targets are forward-looking estimates and not guarantees of future performance.
Is ALNY overvalued or undervalued?
Alnylam Pharmaceuticals, Inc. (ALNY) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 14.5×. The consensus analyst price target of $314.81 is 91% above the current price.
What is Alnylam Pharmaceuticals, Inc.'s profit margin?
Alnylam Pharmaceuticals, Inc. has a net profit margin of 52.8%, which is considered high and reflects strong pricing power. Its gross margin stands at 77.3%, indicating a high-margin business model.
Is Alnylam Pharmaceuticals, Inc.'s revenue growing?
Alnylam Pharmaceuticals, Inc. is reporting solid revenue growth of 16.7% year-over-year. Earnings are also growing at 633.5%, indicating improving profitability.
How much debt does Alnylam Pharmaceuticals, Inc. have?
Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.83×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 2.48×, indicating comfortable short-term liquidity.